Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 13

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 13
---
25 Temporary Headwinds $52 $56 $56 $23 ($8) ($46) (40%) (30%) (20%) (10%) 0% 10% 20% ($80) ($40) $0 $40 $80 $120 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 Adjusted EBITDA Margin Adjusted EBITDA ($M) Adjusted EBITDA Adjusted EBITDA Margin LTM Net Sales at End of Period ($M) LTM Adjusted EBITDA at End of Period ($M) A

CONFIDENTIAL © All rights reserved. Two Seas Capital LP INVESTOR PRESENTATION THE WRONG TIME Staar’s Near - term Headwinds are Abating and Its Prospects Remain Strong 02 PART B

Broadwood Partners, L.P. STAAR’s Near - Term Headwinds Are Abating and Its Prospects Remain Strong 20 ▪ The Company has only just begun to realize benefits of an “organizational reset” that included the appointment of a new CEO, a r ealigned leadership structure, significant cost reductions, optimized inventory management, a manufacturing expansion and product innovation ▪ The Company has spent recent months addressing short - term issues like channel inventory, cost discipline and tariffs, and now ca n turn its attention to growth initiatives, cash flow generation and capital stewardship STAAR’s Recent Actions Have Strengthened the Company ▪ As distributors in China worked off excess channel inventory over the last several months, STAAR’s revenue in Japan, South Ko rea , the Americas and Europe, the Middle East and Africa have continued to grow ▪ STAAR’s ICL procedure is the preferred surgical treatment for refractive vision correction in markets like Japan and is growing in the U. S. while laser vision procedures ( e.g. , LASIK) are declining STAAR’s Core Markets Remain Strong ▪ The number of candidates for STAAR’s ICL procedure is estimated at 1.1 billion and counting, with long - term growth underpinned b y the exploding myopia epidemic 1 The Total Addressable Market Is Expected to Continue to Grow ▪ Surgeons and patients are increasingly turning to EVO ICLs because they do not compromise the integrity of the eye and are fu lly removable; they also offer UV protection and improved vision through a quick procedure with a short recovery ▪ Recent data indicate that ICLs may become the dominant choice STAAR’s